Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $21.75 Consensus Price Target from Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have received a consensus rating of “Buy” from the eight analysts that are covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $21.75.

Several research firms have commented on TRVI. Cantor Fitzgerald began coverage on shares of Trevi Therapeutics in a research report on Tuesday, July 1st. They issued an “overweight” rating and a $25.00 target price for the company. Needham & Company LLC decreased their target price on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Wall Street Zen downgraded shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Finally, D. Boral Capital reissued a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Monday, June 2nd.

Institutional Trading of Trevi Therapeutics

Several large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Trevi Therapeutics by 14.0% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 20,435 shares of the company’s stock worth $112,000 after buying an additional 2,510 shares during the period. Soleus Capital Management L.P. bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth $3,829,000. Rafferty Asset Management LLC bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth $60,000. Rubric Capital Management LP boosted its holdings in shares of Trevi Therapeutics by 88.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after buying an additional 3,993,325 shares during the period. Finally, Octagon Capital Advisors LP boosted its holdings in shares of Trevi Therapeutics by 10.5% during the 2nd quarter. Octagon Capital Advisors LP now owns 3,672,000 shares of the company’s stock worth $20,086,000 after buying an additional 350,000 shares during the period. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $9.75 on Tuesday. The firm has a market cap of $1.19 billion, a PE ratio of -23.21 and a beta of 0.71. The firm’s 50 day moving average price is $7.31 and its two-hundred day moving average price is $6.49. Trevi Therapeutics has a twelve month low of $2.36 and a twelve month high of $9.92.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Equities analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.